It is well established that metabolic changes drive microglial polarization, and a number of pathways, including hypoxia-inducible factor-1alpha (HIF-1), forkhead box P3 (FOXP3), and nuclear factor erythroid 2-related factor 2 (Nrf2) signaling, have been implicated in facilitating these effects [73]
Currently, the dual IGF1/2-neutralizing antibody xentuzumab in combination with everolimus and exemestane is subject to clinical trial in ER + /ErbB2 - breast cancer
This is a key distinction in the Matrixyl vs GHK-Cu landscape
Safety trials: Recombinant human thymosin: A phase I clinical trial assessed the safety of multiple doses of injectable recombinant human thymosin in healthy adults
But its discovery opened up a sprawling field of research into its potent cytoprotective and regenerative properties
Reconstitution technique matters as much as volume